Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Comment by Pyritecubedon Dec 31, 2019 1:53pm

227 Views

Post# 30506126

RE:Shorts increasing, Massive correction implied.

Interesting that you give an assessment exactly opposite of multiple other posters ( long term shareholders) regarding short positions and a correction but neglected to provide any details for your analysis. I suspect your presence here is self serving and your analysis is worthless but by all means please do short this and feel free to post your positions as I am curious to see if you believe in what you say

GLTA (except LastProphet)

Bullboard Posts

Rig Count Soars as Utilization Surpasses Industry Averages